Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
709 stopped studies mapped to Hepatopancreatobiliary Carcinoma and descendants · 93% state a reason
Over the 709 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT00503867 | SIR-Spheres® for the Treatment of Unresectable Hepatocellular Carcinoma | N/A | terminated | Jul 19, 2007 | Sirtex Medical | Low patient recruitment | Enrollment / accrual |
| NCT01562899 | A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors | Phase 1 / Phase 2 | terminated | Mar 26, 2012 | Pfizer | Study was withdrawn due to scientific and business considerations. | Sponsor / business decision |
| NCT03040453 | Immunological Response After Ablative Therapy in the Liver(IRAL) | N/A | withdrawn | Feb 2, 2017 | Karolinska Institutet | poor recruitment | Enrollment / accrual |
| NCT03042780 | FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas | Phase 2 | terminated | Feb 3, 2017 | H. Lee Moffitt Cancer Center and Research Institute | Slow accrual | Enrollment / accrual |
| NCT04262388 | A Multi-Cancer, Multi-State, Platform Study of Durvalumab (MEDI4736) and Oleclumab…(DOME) | Phase 2 | withdrawn | Feb 10, 2020 | University Health Network, Toronto | Overall clinical activity (ORR) for oleclumab + durvalumab is minimal across tumor types and does… | Other (stated, no rule matched) |
| NCT02757391 | CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic… | Phase 1 | terminated | May 2, 2016 | M.D. Anderson Cancer Center | Study halted prematurely and will not resume; participants are no longer being examined or… | Other (stated, no rule matched) |
| NCT04270461 | NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors | Phase 1 | withdrawn | Feb 17, 2020 | Jiujiang University Affiliated Hospital | Study is withdrawn because of administrative reasons | Other (stated, no rule matched) |
| NCT02012231 | Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in… | Phase 1 | terminated | Dec 16, 2013 | Fore Biotherapeutics | not stated | Not stated |
| NCT02558205 | Correlation Between CT Perfusion and Post Y-90 TARE PET/CT Dosimetry | — | withdrawn | Sep 23, 2015 | Rush University Medical Center | unable to rectuir | Other (stated, no rule matched) |
| NCT03925428 | Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and… | Phase 1 | withdrawn | Apr 24, 2019 | National Cancer Institute (NCI) | Other - Protocol moved to Disapproved | Other (stated, no rule matched) |
| NCT02029690 | Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With…(TRAP) | Phase 1 | terminated | Jan 8, 2014 | Polaris Group | not stated | Not stated |
| NCT04044326 | The Safety and Efficacy of Spherical Microwave Ablation for the Treatment of Malignant… | N/A | withdrawn | Aug 5, 2019 | National Taiwan University Hospital | Machine cannot provide | Other (stated, no rule matched) |
| NCT04546802 | HepATocellular Cancer Hcv Therapy Study(HATCHeT) | Phase 3 | withdrawn | Sep 14, 2020 | Bayside Health | Recruitment will be too difficult due to available PBS funded treatment and recent Australian… | Enrollment / accrual |
| NCT03203837 | Biomarker Analyses in Hepatocellular Carcinoma (HCC) Patients Treated With TheraSphere® | — | terminated | Jun 29, 2017 | Northwestern University | Funding Discontinued due to low accrual rate | Enrollment / accrual |
| NCT03644511 | Use of Sorafenib and/or Regorafenib in Liver Cancer (Hepatocellular Carcinoma) Subsequent…(SORAGO-HCC) | — | terminated | Aug 23, 2018 | Bayer | The interest of potential centers is very limited. | Other (stated, no rule matched) |
| NCT03172559 | Radiotherapy Versus no Intervention in Adult Patients With Hepatocellular Carcinoma Not…(RADBRI) | N/A | withdrawn | Jun 1, 2017 | University Health Network, Toronto | Investigator decided not to pursue the study due to other competing studies. | Investigator |
| NCT03511222 | Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors | Phase 1 | terminated | Apr 27, 2018 | Washington University School of Medicine | Low accrual | Enrollment / accrual |
| NCT03890198 | A Phase 1 Study of LCAR-C182A Cells in the Treatment of Advanced Gastric Cancer and… | Early Phase 1 | terminated | Mar 26, 2019 | First Affiliated Hospital Xi'an Jiaotong University | the Preliminary data, progress of this study and the adjustment of the pipeline and strategy . | Sponsor / business decision |
| NCT04395118 | STOP HCC: Mailed HCV Treatment Outreach Program for HCC Prevention for Elevated LFTs(STOP-HCC) | N/A | withdrawn | May 20, 2020 | University of Texas Southwestern Medical Center | Study will not be conducted as a RCT due to limited project timeline. | Other (stated, no rule matched) |
| NCT01092689 | The Role of Meat-borne Carcinogens in Pancreatic Cancer | Phase 1 | withdrawn | Mar 25, 2010 | University of Minnesota | Needed New IND per FDA | Other (stated, no rule matched) |
| NCT02989870 | Sorafenib and Bavituximab Plus SBRT in Unresectable Hepatocellular Carcinoma | Phase 1 | withdrawn | Dec 12, 2016 | H. Lee Moffitt Cancer Center and Research Institute | No Interest. Investigator was unable to enroll any participants on study. | Investigator |
| NCT03480152 | Messenger RNA (mRNA)-Based, Personalized Cancer Vaccine Against Neoantigens Expressed by… | Phase 1 / Phase 2 | terminated | Mar 29, 2018 | National Cancer Institute (NCI) | slow accrual | Enrollment / accrual |
| NCT03801499 | Lenvatinib for Unresectable Intrahepatic Cholangiocarcinoma | Phase 2 | withdrawn | Jan 11, 2019 | Sun Yat-sen University | Protocol modification | Other (stated, no rule matched) |
| NCT04093648 | T Cells co- Expressing a Second Generation Glypican 3-specific Chimeric Antigen Receptor… | Phase 1 | withdrawn | Sep 18, 2019 | Baylor College of Medicine | The key elements of this study were incorporated into another study. | Other (stated, no rule matched) |
| NCT01486134 | Major RF Ablations of Hepatomas Under MR Thermometry Monitoring(ARMTICH) | N/A | terminated | Dec 6, 2011 | Assistance Publique - Hôpitaux de Paris | For technical reasons | Other (stated, no rule matched) |
| NCT02013778 | Phase 1-2 Trial HCQ Plus TACE in Unresectable HCC | Phase 1 / Phase 2 | terminated | Dec 17, 2013 | Abramson Cancer Center at Penn Medicine | Lack of enrollment | Enrollment / accrual |
| NCT01333124 | Preoperative Chemoradiotherapy With Gemcitabine for Resectable Pancreatic Carcinoma | Phase 2 | terminated | Apr 11, 2011 | National Cancer Center, Korea | Recruitment delay | Enrollment / accrual |
| NCT03748927 | Natural History Study of Children and Adults With Fibrolamellar Hepatocellular Carcinoma | — | withdrawn | Nov 21, 2018 | National Cancer Institute (NCI) | slow/insufficient accrual | Enrollment / accrual |
| NCT03172832 | A Trial of Percutaneous vs. Endoscopic Drainage of Suspected Klatskin Tumors(INTERCPT) | N/A | terminated | Jun 1, 2017 | Medical University of South Carolina | Slow accrual; recommended by DSMB. | Enrollment / accrual |
| NCT03990974 | Postoperative Antimicrobial Prophylaxis Versus Placebo for Infection Prevention in HCC…(HCC) | Phase 3 | suspended | Jun 19, 2019 | Sun Yat-sen University | There were difficulties in implementation | Other (stated, no rule matched) |
| NCT04025567 | Vancomycin in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLC) Oral | Phase 2 | withdrawn | Jul 19, 2019 | National Cancer Institute (NCI) | slow/insufficient accrual. | Enrollment / accrual |
| NCT04058964 | Pembrolizumab and PEGPH20 in Treating Patients With Metastatic Pancreatic Cancer | Phase 2 | withdrawn | Aug 16, 2019 | M.D. Anderson Cancer Center | Study withdrawn by supporter | Other (stated, no rule matched) |
| NCT01760616 | Huaier Granule for Prevention of Disease Progression of Hepatocarcinoma After Non-radical… | Phase 4 | terminated | Jan 4, 2013 | Qidong Gaitianli Medicines Co., Ltd | difficult to recruit patients | Enrollment / accrual |
| NCT03277209 | To Assess the Safety of Continuous IV Administration of Plerixafor and Assess Impact on… | Phase 1 | terminated | Sep 8, 2017 | Weill Medical College of Cornell University | terminated due to slow accrual | Enrollment / accrual |
| NCT03079778 | Transarterial Chemoembolization (TACE) With or Without Stereotactic Body Radiotherapy…(TACERT) | N/A | withdrawn | Mar 14, 2017 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Opened up a separate Clinicaltrials.gov trial form, study ID TACE | Other (stated, no rule matched) |
| NCT02580253 | Adjuvant Chemotherapy Based on the Adenosine Triphosphate Tumor Chemosensitivity Assay… | Phase 2 | withdrawn | Oct 20, 2015 | Zhejiang University | no patients enrolled | Enrollment / accrual |
| NCT02867280 | Sorafenib Treatment in Patients With Hepatocellular Carcinoma With Microvascular Invasion… | Phase 3 | terminated | Aug 15, 2016 | Sun Yat-sen University | Midterm analysis showed negative results. | Other (stated, no rule matched) |
| NCT03217253 | Tazemetostat in Treating Patients With Metastatic or Unresectable Solid Tumors or B-Cell… | Phase 1 | withdrawn | Jul 14, 2017 | National Cancer Institute (NCI) | Other - Drug Manufacturer decision to close study | Drug supply |
| NCT03267940 | Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab… | Phase 1 | terminated | Aug 31, 2017 | Halozyme Therapeutics | Sponsor decision | Sponsor / business decision |
| NCT04134468 | MRI Effects of Pegvorhyaluronidase Alfa (PEGPH20) in Pancreatic Ductal Adenocarcinoma | Phase 2 | withdrawn | Oct 22, 2019 | Abramson Cancer Center at Penn Medicine | Halozyme halted development of PEGPH20 following Phase 3 failure. | Other (stated, no rule matched) |
| NCT02743975 | Near-infrared Image Guided Surgery in Pancreatic Adenocarcinoma(PENGUIN) | Phase 1 / Phase 2 | terminated | Apr 19, 2016 | University Medical Center Groningen | Insufficient tumor-to-background ratios in the first three dose groups | Other (stated, no rule matched) |
| NCT03865563 | Selective Transvenous Chemoembolization of Primary Pancreatic Tumors | Phase 1 | withdrawn | Mar 7, 2019 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | We need to make significant adjustments to proposed drug and its delivery method | Other (stated, no rule matched) |
| NCT01431794 | Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for… | Phase 1 / Phase 2 | terminated | Sep 12, 2011 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Study was terminated due to cease in manufacturing of study drug. | Drug supply |
| NCT01923233 | In-Situ Therapeutic Cancer Vaccine for Refractory Liver Cancer | Phase 1 / Phase 2 | withdrawn | Aug 15, 2013 | Mirror Biologics, Inc. | interventional radiologist suffered stroke and unable to perform RFA procedure | Other (stated, no rule matched) |
| NCT01995227 | An Individualized Anti-Cancer Vaccine Study in Patients With HCC | Phase 1 / Phase 2 | withdrawn | Nov 26, 2013 | Mirror Biologics, Inc. | Study site change to Thailand | Other (stated, no rule matched) |
| NCT02289300 | A Study to Evaluate a Study Drug, DCB-BO1202, for Alleviating Liver Fibrosis in Liver… | Phase 2 | withdrawn | Nov 13, 2014 | A2 Healthcare Taiwan Corporation | At sponsor's discretion | Other (stated, no rule matched) |
| NCT04044651 | Lenvatinib Plus Nivolumab Versus Lenvatinib for Advanced Hepatocellular Carcinoma With… | Phase 2 / Phase 3 | withdrawn | Aug 5, 2019 | Shi Ming | Bristol-Myers Squibb company terminated this study | Sponsor / business decision |
| NCT03382886 | Nivolumab and Bevacizumab in Patients With Advanced and or Metastatic Hepatocellular…(NUANCE) | Phase 1 | terminated | Dec 26, 2017 | University of Utah | PI decided to terminate due to low/slow accrual | Enrollment / accrual |
| NCT03433703 | Trial to Evaluate Safety and Efficacy of Treatment of Physician Choice (TPC) Following… | Phase 2 | terminated | Feb 14, 2018 | Eisai Inc. | Study recruitment was stopped due to difficulty in enrolling the targeted number of participants. | Enrollment / accrual |
| NCT00728000 | Phase II Study Of Neoadjuvant Chemotherapy In Borderline Resectable Pancreatic… | Phase 2 | withdrawn | Aug 5, 2008 | University of Cincinnati | study withdrawn due to lack of enrollment | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 24 days agoSource updated Dec 10, 2020source: clinicaltrials